Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition of AbbVie stock equivalent units through director fees and dividend reinvestment.

Summary

• Robert J. Alpern, a director of AbbVie Inc., filed a Form 4 with the SEC on October 2, 2024, reporting changes in beneficial ownership of AbbVie securities.
• The reported transaction occurred on September 30, 2024.
• Alpern acquired 37 stock equivalent units at a price of $197.48 per unit as director fees credited to stock equivalent unit accounts under grantor trusts.
• The balance of stock equivalent units beneficially owned following the reported transaction is 9,655, which includes units acquired through dividend reinvestment.
• These stock equivalent units will be paid in cash generally at age 65 or upon retirement from AbbVie's board.
• The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company through compensation and dividend reinvestment, indicating confidence.

Positives

• The director's acquisition of stock equivalent units demonstrates confidence in AbbVie's future performance.
• Dividend reinvestment further increases the director's stake in the company.

Future Outlook

The stock equivalent units will be paid in cash generally at age 65 or upon retirement from AbbVie's board.

Industry Context

This filing is a routine disclosure of a director's compensation in the form of stock equivalent units, which is a common practice in corporate governance.

Stakeholder Impact

• The director's increased stake aligns their interests with those of shareholders.

Key Dates